NEXGEL, Inc. (NXGL) AI Stock Analysis

NEXGEL, Inc. specializes in the manufacturing of advanced hydrogels and gels characterized by high water content and electron beam cross-linking technology. Originally established as AquaMed Technologies, Inc. and founded in 1997, the company rebranded to NEXGEL in November 2019. Headquartered in Langhorne, Pennsylvania, NEXGEL develops specialized aqueous polymer formulations used across wound care, medical diagnostics, transdermal drug delivery, and cosmetics. With 19 employees, the company focuses on advancing its proprietary hydrogel solutions through ongoing research and development to supply healthcare professionals and consumer product partners globally.

NEXGEL generated a 5-year revenue CAGR of 76.1% from FY2020 to FY2025, with annual revenue rising from $1.6M in FY2021 to $11.4M in FY2025. Revenue growth was 130.1% in FY2021, 32.0% in FY2022, 99.7% in FY2023, 112.5% in FY2024, and 31.5% in FY2025. Gross margin improved from 0.5% in FY2021 to 39.5% in FY2025. Operating margin also narrowed from -165.7% in FY2021 to -29.3% in FY2025, while net margin improved from -277.9% to -26.3%. Net income was -$3.0M in FY2025 compared to -$4.3M in FY2021. For the latest quarter ended June 30, 2026, quarterly revenue growth was 27.8% year-over-year, while trailing twelve month revenue reached $12.1M with an operating margin of -68.0%.

As of June 30, 2026, NEXGEL held $492,000 in cash and short-term investments against total debt of $7.5M, resulting in net debt of $7.0M. Total assets stood at $26.4M, with shareholders' equity of $4.9M and a debt-to-equity ratio of 1.51. Liquidity remains tight, evidenced by a current ratio of 0.43. Operating cash flow was -$1.3M and free cash flow was -$1.4M in FY2025, alongside capital expenditures of $68,000. Over the past five years, the share count changed by -99.6%.

With a market capitalization of $2.7M and an enterprise value of $9.5M, NEXGEL trades at a price-to-sales ratio of 0.2x and an enterprise value-to-revenue ratio of 0.8x. Its price-to-book ratio is 0.5x, and its forward price-to-earnings ratio is 1.4x. These valuation multiples are lower than the median of its US-listed Healthcare peers, which includes a price-to-sales ratio of 4.1x and a forward P/E ratio of 17.3x. NEXGEL's stock declined 88.2% over the trailing 12 months through October 16, 2026, compared to a 16.8% gain for the S&P 500 (SPY).

Wall Street coverage for NEXGEL includes 1 Hold rating and 0 Buy or Sell ratings. The mean price target is $2.00, representing a potential decline of 64.2% from the last close of $5.59 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $15.8M and an EPS of -$18.80. For the following fiscal year, 1 analyst projects revenue of $24.3M and EPS of -$4.40. NEXGEL recorded 0 EPS beats over the past four quarters, and its next earnings date is November 10, 2026.

This page is an AI-written research summary of NEXGEL, Inc. (NXGL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NXGL income statement, NXGL balance sheet, NXGL key metrics, NXGL analyst forecast, NXGL chart. See the NXGL stock overview for the latest quote and news.